Skip to main content

Table 1 Basic characteristics of patients with primary systemic therapy

From: Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer

Characteristic

n

Bone marrow positive

P value

  

n

%

 

Total

157

84

53

-

Menopausal status

   

0.3

   Premenopausal

72

42

58

 

   Postmenopausal

85

42

49

 

Tumor size

   

0.6

   ypT0

24

10

44

 

   ypT1

61

33

54

 

   ypT2–ypT4

73

41

56

 

Nodal status

   

0.5

   ypN negative

75

38

51

 

   ypN positive

82

46

56

 

Estrogen receptor status

   

1.0

   Negative

39

21

54

 

   Positive

118

63

53

 

Progesterone receptor status

   

0.7

   Negative

68

35

52

 

   Positive

89

49

55

 

HER2 status

    

   Negative (score 0/+1 by immunohistochemistry)

115

63

54

0.7

   Positive (score +2/+3 by immunohistochemistry)

39

20

51

 

Grading

   

0.9

   I–II

109

58

53

 

   III

41

21

51

 

Histology

   

0.2

   Ductal

97

48

49

 

   Lobular

33

17

52

 

   Others

27

19

70

 

Primary systemic therapy

   

0.3

   Chemotherapy

142

78

55

 

   Hormonal therapy

15

6

40

 

Response to neoadjuvant systemic therapya

   

<0.05c

   Pathological complete remission

24

10 (4)b

42 (17)b

 

   Partial remissiond

87

42 (11)b

48 (13)b

 

   Stable disease

40

27 (2)b

68 (5)b

 

   Progressive disease

5

4 (0)b

80 (0)b

 
  1. aNot including apoptotic cells (see Table 2). bNumber (percentage) of patients with only apoptotic cells. cComplete remission + partial remission (46%) versus stable disease + progressive disease (69%). dPartial remission also includes patients with clinical complete remission but pathological partial remission.